Q-Line Biotech (NSE:QLINE) Total Receivables: ₹946 Mil (As of Mar. 2025)


NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
12 GF Score
Price ₹546.50
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Total Receivables?

Q-Line Biotech NSE:QLINE -5.15% 12 Total Receivables is ₹946 Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Q-Line Biotech's Total Receivables for the quarter that ended in Mar. 2025 was ₹946 Mil.

Q-Line Biotech Total Receivables Related Terms

Q-Line Biotech Total Receivables Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Total Receivables Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Total Receivables
330.58 264.44 946.38

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Total Receivables 330.58 264.44 946.38
NSE:QLINE
12GF Score
Q-Line Biotech Ltd NSE:QLINE
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹946 Mil mean?
Q-Line Biotech (NSE:QLINE) has a Total Receivables of ₹946 Mil as of Mar. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Total Receivables too high?
Q-Line Biotech's current Total Receivables is ₹946 Mil. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Total Receivables compare to ABT and SYK?
Q-Line Biotech's Total Receivables of ₹946 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Total Receivables is ₹946 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Total Receivables of ₹946 Mil. The current Total Receivables is ₹946 Mil. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Total Receivables is ₹946 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score

Get the complete analysis for NSE:QLINE

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹546.50
Price